专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US10206923B2 Pharmaceutical composition of alogliptin and metformin 有权
公开(公告)号：US10206923B2
公开(公告)日：2019-02-19
申请号：US15753523
申请日：2016-08-17
申请人： TORRENT PHARMACEUTICALS LIMITED
发明人： Jaya Abraham , Suryakant Navale , Pradip Mukhopadhyay , Muzaffar Madny
IPC分类号： A61K31/513 , A61K9/20 , A61K31/155 , A61K45/06
摘要： Present invention relates to a stable pharmaceutical composition comprising intimate mixture of alogliptin and metformin, and suitable pharmaceutically acceptable excipient/s; wherein metformin is present in about 3.3 parts or more parts by weight relative to 100 parts by weight of the total weight of part comprising alogliptin. Invention also encompasses various processes of preparing said pharmaceutical composition and its use in improving glycemic control in adults with type 2 diabetes mellitus.

2. 发明申请

US20180118728A1 NOVEL PYRIDINIUM COMPOUNDS 审中-公开
公开(公告)号：US20180118728A1
公开(公告)日：2018-05-03
申请号：US15564715
申请日：2016-04-05
申请人： TORRENT PHARMACEUTICALS LIMITED
发明人： Chaitanya DUTT , Rameshchandra GUPTA , Manish PATEL , Jaya ABRAHAM , Vivek MISHRA , Amit KESARWANI , Shailesh DESHPANDE , Shital Kumar ZAMBAD , Anoop MATHUR , Jignesh KOTECHA , Sachin LATAD , Anita CHAUDHARI
IPC分类号： C07D409/06 , A61P25/00 , A61K45/06 , A61K31/4436
CPC分类号： C07D409/06 , A61K31/4436 , A61K45/06 , A61P25/00 , C07C53/126
摘要： The present invention relates to novel pyridinium compounds, their isomers, steroisomers, atropisomers, conformers, tautomers, polymorphs, hydrates and solvates. The present invention also encompasses process for preparing novel compounds and pharmaceutical composition of said compounds. The invention further relates to the use of the above mentioned compounds for the preparation of medicament for use as pharmaceuticals.

3. 发明申请

US20070259950A1 Nebivolol and Its Pharmaceutically Acceptable Salts, Process for Preparation and Pharmaceutical Compositions of Nebivolol 有权
标题翻译：奈比洛尔及其药学上可接受的盐，奈比洛尔的制备方法和药物组合物
公开(公告)号：US20070259950A1
公开(公告)日：2007-11-08
申请号：US11658979
申请日：2005-08-01
申请人： Rakesh Sheth , Srinivasarao Attanti , Hasmukh Patel , Vinodkumar Gupta , Sunil Nadkarni
发明人： Rakesh Sheth , Srinivasarao Attanti , Hasmukh Patel , Vinodkumar Gupta , Sunil Nadkarni
IPC分类号： A61K31/35 , C07D311/02
CPC分类号： C07D407/12 , A61K9/2018 , A61K9/2054 , A61K9/2059 , C07D311/58 , C07D407/04
摘要： The present invention provides an improved process for the synthesis of nebivolol or its pharmaceutically acceptable salts, more particularly hydrochloride salt of formula (I). The present invention further provides a new Form T1 of nebivolol and its pharmaceutically acceptable salts. The present invention also provides pharmaceutical compositions and process for the preparation of a solid oral dosage form of nebivolol hydrochloride of formula (I), without the use of wetting agent, and optionally using binder and/or disintegrant.
摘要翻译：本发明提供了奈比洛尔或其药学上可接受的盐，特别是式（I）的盐酸盐的合成的改进方法。本发明还提供奈比洛尔及其药学上可接受的盐的新型T1。本发明还提供了用于制备式（I）盐酸奈必洛尔的固体口服剂型的药物组合物和方法，而不使用润湿剂，并且任选地使用粘合剂和/或崩解剂。

4. 发明申请

US20190169175A1 NOVEL PYRIDINIUM COMPOUNDS 审中-公开
公开(公告)号：US20190169175A1
公开(公告)日：2019-06-06
申请号：US16267224
申请日：2019-02-04
申请人： TORRENT PHARMACEUTICALS LIMITED
发明人： Chaitanya DUTT , Rameshchandra GUPTA , Manish PATEL , Jaya ABRAHAM , Vivek MISHRA , Amit KESARWANI , Shailesh DESHPANDE , Shital Kumar ZAMBAD , Anoop MATHUR , Jignesh KOTECHA , Sachin LATAD , Anita CHAUDHARI
IPC分类号： C07D409/06 , C07C53/126 , A61P25/00 , A61K31/4436 , A61K45/06
摘要： The present invention relates to novel pyridinium compounds, their isomers, steroisomers, atropisomers, conformers, tautomers, polymorphs, hydrates and solvates. The present invention also encompasses process for preparing novel compounds and pharmaceutical composition of said compounds. The invention further relates to the use of the above mentioned compounds for the preparation of medicament for use as pharmaceuticals.

5. 发明授权

US10292948B2 Tapentadol nasal composition 有权
公开(公告)号：US10292948B2
公开(公告)日：2019-05-21
申请号：US15866787
申请日：2018-01-10
申请人： Torrent Pharmaceuticals Limited
发明人： Jaya Abraham , Vivek Mishra , Vipul Mittal , Kiran Chaudhari
IPC分类号： A61K31/137 , A61K47/18 , A61K47/34 , A61K47/38 , A61K47/46 , A61K9/00 , A61P25/04 , A61K47/10 , A61K9/08
摘要： Disclosed herein are pharmaceutical compositions for nasal administration comprising tapentadol, their preparation and their use in the treatment of pain.

6. 发明授权

US09963463B2 Urea-substituted indanes as P38 map kinase inhibitors 有权
公开(公告)号：US09963463B2
公开(公告)日：2018-05-08
申请号：US15505902
申请日：2015-08-27
申请人： TORRENT PHARMACEUTICALS LIMITED
发明人： Milind Rode , Sanjay Srivastava , Davindar Tuli , Deepak Rai , Prashant Gj , Shailesh Deshpande , Rameshchandra Gupta , Vijay Chauthaiwale , Chaitanya Dutt
IPC分类号： A61K31/17 , C07C275/28 , C07D495/04 , C07D487/04 , C07D241/08
CPC分类号： C07D495/04 , C07D241/08 , C07D487/04
摘要： The present invention relates to novel indanyl urea derivatives of formula (I): their pharmaceutically acceptable salts, and their isomers, steroisomers, atropisomers, conformers, tautomers, polymorphs, hydrates and solvates. The present invention also encompasses process for preparing novel compounds and pharmaceutical composition of said compounds. The invention further relates to the use of the compounds for the preparation of medicament for use as pharmaceuticals.

7. 发明申请

US20140045864A1 ACID ADDITION SALTS OF RISPERIDONE AND PHARMACEUTICAL COMPOSITIONS THEREOF 有权
标题翻译：雷米帝酮及其药物组合物的添加剂量
公开(公告)号：US20140045864A1
公开(公告)日：2014-02-13
申请号：US14114379
申请日：2012-04-25
申请人： Sunil Sadanand Nadkarni , Arunkumar Gupta , Manish Parikh , Jaya Abraham , Vivek Mishra
发明人： Sunil Sadanand Nadkarni , Arunkumar Gupta , Manish Parikh , Jaya Abraham , Vivek Mishra
IPC分类号： C07D471/04
CPC分类号： C07D471/04 , A61K31/506 , A61K45/06 , C07D401/14 , C07D403/14
摘要： The present invention relates to a novel acid addition salt of risperidone, wherein acid counterion is selected from the group consisting of pamoic acid, caproic acid, cypionic acid, decanoic acid, camphor sulfonic acid, enanthic acid, palmitic acid, fusidic acid, gluceptic acid, gluconic acid, lactobionic acid, lauric acid, levulinic acid and valeric acid, a process for the preparation and pharmaceutical composition comprising the same. Further, the invention relates to the use of said pharmaceutical composition comprising the acid addition salt of risperidone in the treatment of patient suffering from psychotic disorders.
摘要翻译：本发明涉及一种利培酮的新型酸加成盐，其中酸抗衡离子选自双羟萘酸，己酸，柠檬酸，癸酸，樟脑磺酸，庚酸，棕榈酸，夫西地酸，葡庚糖酸葡萄糖酸，乳糖酸，月桂酸，乙酰丙酸和戊酸，制备方法和包含其的药物组合物。此外，本发明涉及包含利培酮的酸加成盐的所述药物组合物在治疗患有精神病的患者中的用途。

8. 发明申请

US20130157951A1 Pharmaceutical Composition Containing Goserelin for In-Situ Implant 有权
标题翻译：含有戈斯列林原位植入物的药物组合物
公开(公告)号：US20130157951A1
公开(公告)日：2013-06-20
申请号：US13805624
申请日：2011-06-24
申请人： Sunil S. Nadkarni , Jaya Abraham , Amit Kesarwani , Astha Parmar
发明人： Sunil S. Nadkarni , Jaya Abraham , Amit Kesarwani , Astha Parmar
IPC分类号： A61K38/25
CPC分类号： A61K38/25 , A61K9/0024 , A61K38/09 , A61K47/34
摘要： The present invention provides a pharmaceutical composition capable of forming in-situ implant comprising goserelin or its pharmaceutically acceptable salts thereof, biodegradable polymer and a biocompatible organic solvent wherein the biocompatible organic solvent is miscible to dispersible in aqueous medium or body fluid. The present invention further provides a process for the preparation of pharmaceutical composition capable of forming in-situ implant. A kit containing composition for in-situ implant is provided comprising a first vial comprising a composition comprising a biodegradable polymer and a biocompatible organic solvent; wherein the biocompatible organic solvent is miscible to dispersible in aqueous medium or body fluid; and a second vial comprising goserelin acetate.
摘要翻译：本发明提供能够形成原位植入物的药物组合物，其包含戈舍瑞林或其药学上可接受的盐，可生物降解的聚合物和生物相容性有机溶剂，其中生物相容性有机溶剂可混溶于水性介质或体液中。本发明还提供了一种制备能够形成原位植入物的药物组合物的方法。提供了一种用于原位植入物的含有组合物的试剂盒，其包括含有可生物降解的聚合物和生物相容性有机溶剂的组合物的第一小瓶; 其中所述生物相容性有机溶剂可混溶于水性介质或体液中; 和包含醋酸戈舍瑞林的第二小瓶。

9. 发明授权

US08268352B2 Modified release composition for highly soluble drugs 有权
标题翻译：用于高度可溶性药物的改性释放组合物
公开(公告)号：US08268352B2
公开(公告)日：2012-09-18
申请号：US11134632
申请日：2005-05-19
申请人： Navin Vaya , Rajesh Singh Karan , Sunil Sadanand Nadkarni , Vinod Kumar Gupta
发明人： Navin Vaya , Rajesh Singh Karan , Sunil Sadanand Nadkarni , Vinod Kumar Gupta
IPC分类号： A61K9/26 , A61K9/20
CPC分类号： A61K9/2081 , A61K9/5021
摘要： A novel modified release dosage form comprising of a high solubility active ingredient, which utilizes dual retard technique to effectively reduce the quantity of release controlling agents. Present invention can optionally comprise additionally another active ingredient as an immediate release form or modified release form. Present invention also relates to a process for preparing the said formulation.
摘要翻译：一种新的改性释放剂型，其包含高溶解度活性成分，其利用双延迟技术来有效减少释放控制剂的量。本发明可任选地另外包含作为立即释放形式或改变释放形式的另一活性成分。本发明还涉及制备所述制剂的方法。

10. 发明授权

US08263125B2 Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients 有权
标题翻译：用于高剂量 - 高溶解度活性成分的剂型，可提供活性成分的即时释放和释放
公开(公告)号：US08263125B2
公开(公告)日：2012-09-11
申请号：US11134633
申请日：2005-05-19
申请人： Navin Vaya , Rajesh Singh Karan , Sunil Sadanand Nadkarni , Vinod Kumar Gupta
发明人： Navin Vaya , Rajesh Singh Karan , Sunil Sadanand Nadkarni , Vinod Kumar Gupta
IPC分类号： A61K9/26 , A61K9/20
CPC分类号： A61K9/209 , A61K9/2077 , A61K9/2081 , A61K31/155 , A61K31/19 , A61K31/22 , A61K31/4025 , A61K31/455 , A61K31/53
摘要： A dosage form comprising of a high dose, high solubility active ingredient as modified release and a low dose active ingredient as immediate release where the weight ratio of immediate release active ingredient and modified release active ingredient is from 1:10 to 1:15000 and the weight of modified release active ingredient per unit is from 500 mg to 1500 mg; a process for preparing the dosage form.
摘要翻译：一种剂型，其包含高剂量，高溶解度的活性成分作为调节释放剂和低剂量活性成分作为立即释放，其中速释活性成分和释放活性成分的重量比为1:10至1:15000，每单位改性释放活性成分的重量为500mg至1500mg; 制备剂型的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式